Holen Sie sich die Stockscreener-App
4.76
0.42%
0.00
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Is BioAge Labs Inc. a good long term investmentSignificant capital appreciation - Autocar Professional
What drives BioAge Labs Inc. stock priceRapid capital growth - jammulinksnews.com
What analysts say about BioAge Labs Inc. stockUnprecedented market success - jammulinksnews.com
BioAge Labs Inc. Stock Analysis and ForecastRapidly expanding wealth - Autocar Professional
BIOA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by BioAge Labs, Inc. - ACCESS Newswire
Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load? - simplywall.st
What makes BioAge Labs Inc. stock price move sharplyMarket Trend Watch - Newser
Drugmaker Fights Claims Over 'Misleading' IPO Statements - Law360
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO - MSN
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Levi & Korsinsky Announces an Investigation on Behalf of BioAge Labs, Inc. (BIOA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
BioAge Labs, Inc.(NasdaqGS: BIOA) dropped from Russell 3000 Growth Index - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Shareholders to Connect - ACCESS Newswire
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions - The Manila Times
BioAge Labs' APJ Agonism: A New Frontier in Combating Obesity and Heart Failure Comorbidities? - AInvest
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - ACCESS Newswire
BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener
BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance
BioAge Labs Launches Initiative to Analyze Over 17,000 HUNT Biobank Samples for Drug Discovery in Aging-Related Diseases - Nasdaq
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com
Healthcare companies chase cures and capital in South Florida - Sun Sentinel
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire
BioAge Labs Elects Directors at Annual Meeting - TipRanks
BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):